A strong team with experience and know-how

Management

Dr. Walter von Horstig - Vorstand
Dr. Walter von Horstig

Dr. Walter von Horstig

Dr. von Horstig studied business administration at the University of Mannheim and St. Gall, where he also completed his PhD thesis. From 1993 to 1998 he worked as a management consultant for Bain & Company and the ABB Group. From 1999 to 2004, Dr. von Horstig was founder, managing director and board member of several start-up companies in the service and biotech sector, before joining the Underberg Group as Commercial Director. From 2009 to the beginning of 2017, Dr. von Horstig was the Managing Director of a DRK blood donation service and was responsible for a fundamental economic restructuring of the company. In April 2017, he joined the M1 Med Beauty Berlin GmbH as Managing Director before being appointed to the Management Board of M1 Kliniken AG in October 2017.

Board

Dr. Albert Wahl
Uwe Zimdars
Prof. Dr. Dr. Sabine Meck

Latest news

| Investor News

  • Group revenue falls to just under EUR 139 million (EUR 165 million in H1-2021)
  • Group EBITDA amounts to EUR 7.4 million (previous year: EUR 9.9 million); EBIT amounts to EUR 4.5 million (previous year: EUR 7.1 million)
  • Beauty: Increase in treatment and sales figures; five new centres already opened in 2022; no influence of the deteriorating consumer climate so far

| Investor News

  • Group turnover falls to EUR 63.5 million (EUR 80.8 million in Q1-2021)
  • Group EBITDA amounts to EUR 4.2 million (previous year: EUR 4.0 million); EBIT amounts to EUR 2.8 million (previous year: EUR 2.6 million)
  • Beauty: Increase in turnover by 6 % to EUR 13.8 million (previous year: EUR 13.0 million); number of treatments rises by 9 % to almost 89 thousand.
  • Trade: Continuation of operational optimisations and portfolio streamlining

| Investor News

  • Supervisory Board adopts the 2021 annual financial statements of M1 Kliniken AG, which have been audited with unqualified audit opinions
  • Turnover almost doubles to almost 315 million euros. Group operating result (EBIT) almost tripled to €12.1 million (€4.4 million in 2020)
  • The Supervisory Board and the Executive Board propose to the Annual General Meeting that the balance sheet profit be carried forward in full to new account. Investments in sustainable growth planned.

| Investor News

M1 Kliniken AG publishes preliminary figures for the 2021 financial year. In the past financial year, the M1 Group was able to significantly expand its market position in the field of beauty medicine and opened seven new specialist centres in the German home market alone. The subsidiary Haemato AG set a cornerstone for the development of the own-brand business with the in-licensing of a botulinum toxin product from Huons Biopharma. The start of the clinical approval trial is planned for the second half of 2022.